{
    "guideline_id": "2024CSCO食管癌诊疗指南- .txt",
    "cancer_info": {
        "cancer_name": "Esophageal Cancer"
    },
    "clinical_recommendations": [
        {
            "clinical_context": "Early-stage esophageal cancer (cT1a-T1b)",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "Endoscopic resection (EMR/ESD) ± radiofrequency ablation",
            "treatment_line": "First-line",
            "biomarker_requirements": [],
            "recommendation_level": "Level I Recommendation",
            "evidence_level": "Evidence 1A"
        },
        {
            "clinical_context": "Resectable locally advanced esophageal cancer",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "Neoadjuvant concurrent chemoradiotherapy (cisplatin/paclitaxel + radiotherapy 40-50Gy) → surgery",
            "treatment_line": "Neoadjuvant",
            "biomarker_requirements": [],
            "recommendation_level": "Level I Recommendation",
            "evidence_level": "Evidence 1A"
        },
        {
            "clinical_context": "Resectable locally advanced esophageal cancer",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "Neoadjuvant immunotherapy + chemotherapy: camrelizumab + albumin-bound paclitaxel/cisplatin or paclitaxel/cisplatin",
            "treatment_line": "Neoadjuvant",
            "biomarker_requirements": [],
            "recommendation_level": "Level I Recommendation",
            "evidence_level": "Evidence 1A"
        },
        {
            "clinical_context": "Unresectable esophageal cancer",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "Definitive concurrent chemoradiotherapy (cisplatin/5-FU or paclitaxel + radiotherapy 50-60Gy)",
            "treatment_line": "First-line",
            "biomarker_requirements": [],
            "recommendation_level": "Level I Recommendation",
            "evidence_level": "Evidence 1A"
        },
        {
            "clinical_context": "Postoperative adjuvant therapy for adenocarcinoma",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "Oxaliplatin + capecitabine",
            "treatment_line": "Adjuvant",
            "biomarker_requirements": [],
            "recommendation_level": "Level I Recommendation",
            "evidence_level": "Evidence 1A"
        },
        {
            "clinical_context": "Postoperative adjuvant therapy for squamous cell carcinoma with residual disease after neoadjuvant therapy",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "Nivolumab",
            "treatment_line": "Adjuvant",
            "biomarker_requirements": [],
            "recommendation_level": "Level I Recommendation",
            "evidence_level": "Evidence 1A"
        },
        {
            "clinical_context": "Metastatic/recurrent HER2-positive adenocarcinoma",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "Trastuzumab + cisplatin/oxaliplatin + 5-FU/capecitabine",
            "treatment_line": "First-line",
            "biomarker_requirements": [
                {
                    "biomarker_name": "HER2",
                    "status": "Positive (IHC 3+ or FISH+)",
                    "testing_guidance": "Required for treatment indication"
                }
            ],
            "recommendation_level": "Level I Recommendation",
            "evidence_level": "Evidence 1A"
        },
        {
            "clinical_context": "Metastatic/recurrent HER2-negative adenocarcinoma or squamous cell carcinoma with PD-L1 CPS≥5",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "Immunotherapy (pembrolizumab/sintilimab) + chemotherapy",
            "treatment_line": "First-line",
            "biomarker_requirements": [
                {
                    "biomarker_name": "PD-L1",
                    "status": "CPS≥5",
                    "testing_guidance": "Required for treatment selection; use 22C3 assay"
                }
            ],
            "recommendation_level": "Level I Recommendation",
            "evidence_level": "Evidence 1A"
        },
        {
            "clinical_context": "Metastatic/recurrent HER2-negative adenocarcinoma or squamous cell carcinoma with PD-L1 CPS<5",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "Chemotherapy alone (cisplatin + 5-FU/paclitaxel-based)",
            "treatment_line": "First-line",
            "biomarker_requirements": [
                {
                    "biomarker_name": "PD-L1",
                    "status": "CPS<5",
                    "testing_guidance": "Required for treatment selection; use 22C3 assay"
                }
            ],
            "recommendation_level": "Level I Recommendation",
            "evidence_level": "Evidence 1A"
        },
        {
            "clinical_context": "Second-line or later therapy for squamous cell carcinoma",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "Camrelizumab or anlotinib",
            "treatment_line": "Second-line",
            "biomarker_requirements": [],
            "recommendation_level": "Level I Recommendation",
            "evidence_level": "Evidence 1A"
        },
        {
            "clinical_context": "Second-line or later therapy for adenocarcinoma",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "Ramucirumab + paclitaxel",
            "treatment_line": "Second-line",
            "biomarker_requirements": [],
            "recommendation_level": "Level I Recommendation",
            "evidence_level": "Evidence 1A"
        },
        {
            "clinical_context": "Third-line therapy for HER2-positive adenocarcinoma",
            "recommendation_type": "Treatment Plan",
            "recommendation_content": "Vedotin monoclonal antibody (维迪西妥单抗)",
            "treatment_line": "Third-line",
            "biomarker_requirements": [
                {
                    "biomarker_name": "HER2",
                    "status": "Positive (IHC 3+ or FISH+)",
                    "testing_guidance": "Required for treatment indication"
                }
            ],
            "recommendation_level": "Level II Recommendation",
            "evidence_level": "Evidence 2"
        }
    ],
    "biomarker_clinical_significance": {
        "clinical_significance": "PD-L1 CPS predicts efficacy of immunotherapy (e.g., CPS≥5 for first-line immunotherapy combined with chemotherapy, CPS≥10 for pembrolizumab in second-line). HER2 positivity predicts efficacy of HER2-targeted therapy (e.g., trastuzumab). MMR/MSI status (dMMR/MSI-H) may predict benefit from immunotherapy in adenocarcinoma."
    },
    "tcm_recommendations": []
}